FCPA Compliance and Ethics Report-Episode 82, continued fallout from GSK in China
A Conversation with Tim Gardner on Asia Restructirungs
Examining Trends in Worldwide Design IP Filings
A Conversation with Lindsay Chu on Asia Restructurings
A Conversation with Rajiv Gupta on Asia Restructurings
The Changing Landscape of Intellectual Property in China
A Conversation with Ben Simpfendorfer on Asia Restructurings
A Conversation with David Heller on Asia Restructurings
A Conversation with Robyn Meredith on Asia Restructurings
Polsinelli Podcast - Conducting Business in China
FCPA Compliance and Ethics Report-Episode 15-GSK in China: a Game Changer in Compliance
China Outbound Investment
Russian Mergers & Acquisitions Market - Challenges and Opportunities
The FCPA Compliance and Ethics Report, Episode 3
China's Export Policy Changes After U.S. Antitrust Case
Jaffe Sees 'A Lot' of IPOs in 2013 'Pipeline'
How to Protect Your Company From Hackers
Aquila: M&A Looking Up in 2013; "The Negatives Are Built In"
More Law Firm Mergers in 2013
PRC based issuers, and the reliability of the financial information for these companies, continued to be a key issue for the Commission as well as the PCAOB in 2013. An action brought by the Commission against Subaye, Inc....more
There have been some major developments in the trade, Customs fraud, patents, US/Chinese antitrust, and securities areas.
I have just returned from a trip of more than 2 weeks in China. While in China, we discussed US...more
Do the intentions behind enforcement of domestic or international anti-corruption laws matter? Or is ‘the law the law’ and it really does not matter what a government’s motives are in enforcing laws that it has on the books....more
Discussion and Analysis -
Most of us have seen those top-rated TV commercials for a wireless provider featuring a conservatively dressed man sitting at a little table with several children and asking them, “Is it...more
CHINA’S NEW WAVE OF REGULATORY ENFORCEMENT: WHAT MULTINATIONALS NEED TO KNOW -
Since Xi Jiping became China’s leader this year, the PRC has seen the launch of an unprecedented, sweeping government campaign to tackle...more
Since Xi Jiping became China’s leader this year, the PRC has seen the launch of an unprecedented, sweeping government campaign to tackle corruption.
The wave of enforcement action against corrupt officials that...more
The regulatory enforcement environment in China remains tense, as both the Chinese government and media bring new actions and allegations against life sciences manufacturers in both the pharmaceutical and device sectors. We...more
IN THIS ISSUE:
- A new wave of regulatory enforcement actions in China – Are we witnessing a prolonged enforcement cycle?
- Update on recent decisions
- Australia’s innovation patent – The...more
Can you imagine being the public relations director for China these days?...more
The recent enforcement of Chinese anti-bribery laws against British pharmaceutical company GlaxoSmithKline (GSK) highlights the compliance challenges faced by foreign companies operating in China....more
The Chinese government investigation of GlaxoSmithKline (GSK) for alleged bribery has been front page news in China for several weeks. The press has also featured numerous other stories about a broader investigation into...more
The headlines get worse and worse. More companies under investigation....more
In Parts II and III of my review of the Eli Lilly and Company (Lilly) Foreign Corrupt Practices Act (FCPA) enforcement action brought by the Securities and Exchange Commission (SEC), I will discuss some the processes and...more
Back to Top